Literature DB >> 18452558

Frequent silencing of a putative tumor suppressor gene melatonin receptor 1 A (MTNR1A) in oral squamous-cell carcinoma.

Erina Nakamura1, Ken-ichi Kozaki, Hitoshi Tsuda, Emina Suzuki, Atiphan Pimkhaokham, Gou Yamamoto, Tarou Irie, Tetsuhiko Tachikawa, Teruo Amagasa, Johji Inazawa, Issei Imoto.   

Abstract

Array-based comparative genomic hybridization (array-CGH) has good potential for the high-throughput identification of genetic aberrations in cell genomes. In the course of a program to screen a panel of 21 oral squamous-cell carcinoma (OSCC) cell lines for genome-wide copy-number aberrations by array-CGH using our in-house bacterial artificial chromosome arrays, we identified a frequent homozygous deletion at 4q35 loci with approximately 1 Mb in extent. Among the seven genes located within this region, the expression of the melatonin receptor 1 A (MTNR1A) messenger RNA (mRNA) was not detected or decreased in 35 out of the 39 (89%) OSCC cell lines, but was detected in immortalized normal oral epithelial cell line, and was restored in gene-silenced OSCC cells without its homozygous loss after treatment with 5-aza-2'-deoxycytidine. The hypermethylation of the CpG (cytosine and guanine separated by phosphate) island in the promoter region of MTNR1A was inversely correlated with its expression in OSCC lines without a homozygous deletion. Methylation of this CpG island was also observed in primary OSCC tissues. In an immunohistochemical analysis of 50 primary OSCC tumors, the absence of immunoreactive MTNR1A was significantly associated with tumor size and a shorter overall survival in patients with OSCC tumors, and seems to be an independent prognosticator in a multivariate analysis. Exogenous restoration of MTNR1A expression inhibited the growth of OSCC cells lacking its expression. Together with the known tumor-suppressive function of melatonin and MTNR1A in various tumors, our results indicate MTNR1A to be the most likely target for epigenetic silencing at 4q35 and to play a pivotal role during oral carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18452558     DOI: 10.1111/j.1349-7006.2008.00838.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  26 in total

1.  Frequent deletion of ING2 locus at 4q35.1 associates with advanced tumor stage in head and neck squamous cell carcinoma.

Authors:  Silvia S Borkosky; Mehmet Gunduz; Hitoshi Nagatsuka; Levent Bekir Beder; Esra Gunduz; Mahmoud A L Sheikh Ali; Andrea P Rodriguez; Mehmet Zeynel Cilek; Susumu Tominaga; Noboru Yamanaka; Kenji Shimizu; Noriyuki Nagai
Journal:  J Cancer Res Clin Oncol       Date:  2008-11-08       Impact factor: 4.553

Review 2.  Influence of photoperiod on hormones, behavior, and immune function.

Authors:  James C Walton; Zachary M Weil; Randy J Nelson
Journal:  Front Neuroendocrinol       Date:  2010-12-13       Impact factor: 8.606

3.  Melatonin Synergizes the Chemotherapeutic Effect of Cisplatin in Ovarian Cancer Cells Independently of MT1 Melatonin Receptors.

Authors:  Agata Zemła; Irmina Grzegorek; Piotr Dzięgiel; Karolina Jabłońska
Journal:  In Vivo       Date:  2017 Sep-Oct       Impact factor: 2.155

4.  Role of DNA methylation in head and neck cancer.

Authors:  Semra Demokan; Nejat Dalay
Journal:  Clin Epigenetics       Date:  2011-07-09       Impact factor: 6.551

5.  Genomic profiling of advanced-stage oral cancers reveals chromosome 11q alterations as markers of poor clinical outcome.

Authors:  Srikant Ambatipudi; Moritz Gerstung; Ravindra Gowda; Prathamesh Pai; Anita M Borges; Alejandro A Schäffer; Niko Beerenwinkel; Manoj B Mahimkar
Journal:  PLoS One       Date:  2011-02-28       Impact factor: 3.240

6.  Interactions between environmental factors and melatonin receptor type 1A polymorphism in relation to oral cancer susceptibility and clinicopathologic development.

Authors:  Feng-Yan Lin; Chiao-Wen Lin; Shun-Fa Yang; Wei-Jiunn Lee; Yung-Wei Lin; Liang-Ming Lee; Junn-Liang Chang; Wei-Chun Weng; Chien-Huang Lin; Ming-Hsien Chien
Journal:  PLoS One       Date:  2015-03-25       Impact factor: 3.240

7.  Salivary melatonin in oral squamous cell carcinoma patients.

Authors:  Ivan Salarić; Ivana Karmelić; Jasna Lovrić; Ksenija Baždarić; Marko Rožman; Igor Čvrljević; Ivan Zajc; Davor Brajdić; Darko Macan
Journal:  Sci Rep       Date:  2021-06-24       Impact factor: 4.379

8.  miR-655 Is an EMT-suppressive microRNA targeting ZEB1 and TGFBR2.

Authors:  Yosuke Harazono; Tomoki Muramatsu; Hironori Endo; Narikazu Uzawa; Tatsuyuki Kawano; Kiyoshi Harada; Johji Inazawa; Ken-ichi Kozaki
Journal:  PLoS One       Date:  2013-05-14       Impact factor: 3.240

9.  Expression of melatonin receptors in triple negative breast cancer (TNBC) in African American and Caucasian women: relation to survival.

Authors:  Gabriela Oprea-Ilies; Erhard Haus; Linda Sackett-Lundeen; Yuan Liu; Lauren McLendon; Robert Busch; Amy Adams; Cynthia Cohen
Journal:  Breast Cancer Res Treat       Date:  2012-12-19       Impact factor: 4.872

10.  Melatonin and oral cavity.

Authors:  Murat İnanç Cengiz; Seda Cengiz; Hom-Lay Wang
Journal:  Int J Dent       Date:  2012-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.